Calico announces FDA Breakthrough Therapy Designation for fosigotifator
The designation is for treating Vanishing White Matter disease, based on early clinical evidence.
See the latest news and media coverage for Calico. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company focused on aging and healthspan
calicolabs.comLast updated
In short: Calico advanced its therapeutic pipeline for aging and rare diseases through FDA designations, key leadership hires, and collaborations.
The designation is for treating Vanishing White Matter disease, based on early clinical evidence.
The designation was granted for ABBV-CLS-628, an anti-PAPP-A antibody developed with AbbVie, which also has Fast Track status and is in Phase 2.
ABBV-CLS-628, an anti-PAPP-A monoclonal antibody developed with AbbVie, is in Phase 2 trials for ADPKD.
The approach combines CRISPR and cell imaging to create a genome-wide atlas of cell morphology, enabling scalable study of aging and disease.
In 2013, Google launched Calico Life Sciences to develop drugs for the treatment of ageing and age-related diseases. It was an ambitious plan, prompting Time...
AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece...
As is often the case in the world of scientific research partnerships, almost as quickly as a new deal begins, another ends. Popular spit-in-a-tube genetics-testing...
AbbVie and Google parent company Alphabet are each committing $500 million to continue funding the scientists researching aging at the ambitious Alphabet unit called Calico...
Track Calico and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Calico and other trending companies.